These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Clinical and pharmacy utilization outcomes with brand to generic antiepileptic switches in patients with epilepsy. Erickson SC; Le L; Ramsey SD; Solow BK; Zakharyan A; Stockl KM; Harada AS; Curtis B Epilepsia; 2011 Jul; 52(7):1365-71. PubMed ID: 21692778 [TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness of generic and brand-name medication use: A database study of US health insurance claims. Desai RJ; Sarpatwari A; Dejene S; Khan NF; Lii J; Rogers JR; Dutcher SK; Raofi S; Bohn J; Connolly JG; Fischer MA; Kesselheim AS; Gagne JJ PLoS Med; 2019 Mar; 16(3):e1002763. PubMed ID: 30865626 [TBL] [Abstract][Full Text] [Related]
4. Comparison of brand versus generic antiepileptic drug adverse event reporting rates in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS). Rahman MM; Alatawi Y; Cheng N; Qian J; Plotkina AV; Peissig PL; Berg RL; Page D; Hansen RA Epilepsy Res; 2017 Sep; 135():71-78. PubMed ID: 28641219 [TBL] [Abstract][Full Text] [Related]
5. Brand name to generic substitution of antiepileptic drugs does not lead to seizure-related hospitalization: a population-based case-crossover study. Polard E; Nowak E; Happe A; Biraben A; Oger E; Pharmacoepidemiol Drug Saf; 2015 Nov; 24(11):1161-9. PubMed ID: 26395769 [TBL] [Abstract][Full Text] [Related]
6. Seizure outcomes following the use of generic versus brand-name antiepileptic drugs: a systematic review and meta-analysis. Kesselheim AS; Stedman MR; Bubrick EJ; Gagne JJ; Misono AS; Lee JL; Brookhart MA; Avorn J; Shrank WH Drugs; 2010 Mar; 70(5):605-21. PubMed ID: 20329806 [TBL] [Abstract][Full Text] [Related]
7. Generic antiepileptic drugs-Safe or harmful in patients with epilepsy? Holtkamp M; Theodore WH Epilepsia; 2018 Jul; 59(7):1273-1281. PubMed ID: 29894004 [TBL] [Abstract][Full Text] [Related]
8. Generic lamotrigine versus brand-name Lamictal bioequivalence in patients with epilepsy: A field test of the FDA bioequivalence standard. Ting TY; Jiang W; Lionberger R; Wong J; Jones JW; Kane MA; Krumholz A; Temple R; Polli JE Epilepsia; 2015 Sep; 56(9):1415-24. PubMed ID: 26201987 [TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness of generic and brand-name statins on patient outcomes: a cohort study. Gagne JJ; Choudhry NK; Kesselheim AS; Polinski JM; Hutchins D; Matlin OS; Brennan TA; Avorn J; Shrank WH Ann Intern Med; 2014 Sep; 161(6):400-7. PubMed ID: 25222387 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of innovator versus generic drugs in patients with epilepsy: a systematic review. Talati R; Scholle JM; Phung OP; Baker EL; Baker WL; Ashaye A; Kluger J; Coleman CI; White CM Pharmacotherapy; 2012 Apr; 32(4):314-22. PubMed ID: 22461121 [TBL] [Abstract][Full Text] [Related]
11. Treatment persistence and adherence and their consequences on patient outcomes of generic versus brand-name statins routinely used to treat high cholesterol levels in Spain: a retrospective cost-consequences analysis. Sicras-Mainar A; Sánchez-Álvarez L; Navarro-Artieda R; Darbà J Lipids Health Dis; 2018 Dec; 17(1):277. PubMed ID: 30522491 [TBL] [Abstract][Full Text] [Related]
12. Clinical consequences of generic substitution of lamotrigine for patients with epilepsy. LeLorier J; Duh MS; Paradis PE; Lefebvre P; Weiner J; Manjunath R; Sheehy O Neurology; 2008 May; 70(22 Pt 2):2179-86. PubMed ID: 18505997 [TBL] [Abstract][Full Text] [Related]
13. Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes. Andermann F; Duh MS; Gosselin A; Paradis PE Epilepsia; 2007 Mar; 48(3):464-9. PubMed ID: 17346246 [TBL] [Abstract][Full Text] [Related]
14. Relationship of antiepileptic drugs to generic brittleness in patients with epilepsy. Das S; Jiang X; Jiang W; Ting TY; Polli JE Epilepsy Behav; 2020 Apr; 105():106936. PubMed ID: 32092462 [TBL] [Abstract][Full Text] [Related]
15. Economic burden associated with the use of generic antiepileptic drugs in the United States. Helmers SL; Paradis PE; Manjunath R; Duh MS; Lafeuille MH; Latrémouille-Viau D; Lefebvre P; Labiner DM Epilepsy Behav; 2010 Aug; 18(4):437-44. PubMed ID: 20580619 [TBL] [Abstract][Full Text] [Related]
16. Refilling and switching of antiepileptic drugs and seizure-related events. Gagne JJ; Avorn J; Shrank WH; Schneeweiss S Clin Pharmacol Ther; 2010 Sep; 88(3):347-53. PubMed ID: 20631693 [TBL] [Abstract][Full Text] [Related]
17. Generic substitution of antiepileptic drugs: a systematic review of prospective and retrospective studies. Yamada M; Welty TE Ann Pharmacother; 2011 Nov; 45(11):1406-15. PubMed ID: 22028417 [TBL] [Abstract][Full Text] [Related]
18. The risks and costs of multiple-generic substitution of topiramate. Duh MS; Paradis PE; Latrémouille-Viau D; Greenberg PE; Lee SP; Durkin MB; Wan GJ; Rupnow MF; LeLorier J Neurology; 2009 Jun; 72(24):2122-9. PubMed ID: 19528520 [TBL] [Abstract][Full Text] [Related]
19. Generic escitalopram initiation and substitution among Medicare beneficiaries: A new user cohort study. Li C; Chen L; Huo N; Mishuk AU; Hansen RA; Harris I; Kiptanui Z; Wang Z; Qian J PLoS One; 2020; 15(4):e0232226. PubMed ID: 32353006 [TBL] [Abstract][Full Text] [Related]
20. Are generic drugs really inferior medicines? Moore N; Berdaï D; Bégaud B Clin Pharmacol Ther; 2010 Sep; 88(3):302-4. PubMed ID: 20725079 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]